Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of
GRN163L when administered to patients with refractory or relapsed multiple myeloma.